PDS Biotechnology Corp (PDSB)
3.49
-0.04
(-1.13%)
USD |
NASDAQ |
May 17, 16:00
3.49
0.00 (0.00%)
After-Hours: 20:00
PDS Biotechnology SG&A Expense (Quarterly): 3.394M for March 31, 2024
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 3.394M |
| December 31, 2023 | 2.941M |
| September 30, 2023 | 4.071M |
| June 30, 2023 | 4.691M |
| March 31, 2023 | 3.579M |
| December 31, 2022 | 2.666M |
| September 30, 2022 | 2.926M |
| June 30, 2022 | 3.331M |
| March 31, 2022 | 3.318M |
| December 31, 2021 | 2.932M |
| September 30, 2021 | 3.274M |
| June 30, 2021 | 2.342M |
| March 31, 2021 | 1.636M |
| December 31, 2020 | 1.550M |
| September 30, 2020 | 1.846M |
| June 30, 2020 | 1.522M |
| March 31, 2020 | 2.060M |
| December 31, 2019 | 1.623M |
| September 30, 2019 | 3.069M |
| June 30, 2019 | 2.384M |
| Date | Value |
|---|---|
| March 31, 2019 | 3.906M |
| December 31, 2018 | 12.84M |
| September 30, 2018 | 0.5162M |
| June 30, 2018 | 0.3984M |
| March 31, 2018 | 0.5358M |
| December 31, 2017 | 5.290M |
| September 30, 2017 | 3.990M |
| June 30, 2017 | 4.173M |
| March 31, 2017 | 4.202M |
| December 31, 2016 | 4.16M |
| September 30, 2016 | 3.552M |
| June 30, 2016 | 3.289M |
| March 31, 2016 | 3.686M |
| December 31, 2015 | 3.606M |
| September 30, 2015 | 1.977M |
| June 30, 2015 | 1.765M |
| March 31, 2015 | 1.311M |
| December 31, 2014 | 1.180M |
| September 30, 2014 | 1.141M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
1.522M
Minimum
Jun 2020
4.691M
Maximum
Jun 2023
2.758M
Average
2.929M
Median
SG&A Expense (Quarterly) Benchmarks
| Syros Pharmaceuticals Inc | 6.266M |
| PAVmed Inc | 10.99M |
| Palatin Technologies Inc | 2.033M |
| iBio Inc | 2.961M |
| Chromocell Therapeutics Corp | 1.243M |